These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1526714)

  • 1. [Tumor markers in the diagnosis of solid tumors].
    Koch OM
    Internist (Berl); 1992 Aug; 33(8):W79-86. PubMed ID: 1526714
    [No Abstract]   [Full Text] [Related]  

  • 2. [Tumor markers--how they should be applied].
    Stieber P; Heinemann V; Schalhorn A
    MMW Fortschr Med; 2005 May; 147(20):35, 37-9. PubMed ID: 15957858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Is follow-up of breast cancer with CEA and CA 15-3 justified?].
    Fritsche E; Benz J
    Helv Chir Acta; 1992 May; 59(1):225-9. PubMed ID: 1526832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?].
    Sevelda P; Rosen A; Barrada M; Gober S; Vavra N; Salzer H
    Gynakol Rundsch; 1990; 30 Suppl 1():210-1. PubMed ID: 2079273
    [No Abstract]   [Full Text] [Related]  

  • 5. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K].
    Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C
    Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dukes C2 colon cancer: what is appropriate follow-up?
    Semin Oncol; 1995 Jun; 22(3):xix; discussion xix-xx passim. PubMed ID: 7777864
    [No Abstract]   [Full Text] [Related]  

  • 7. False elevation of serum CA 15-3 levels in patients under follow-up for breast cancer.
    Aguiar-Bujanda D; Bohn-Sarmiento U; Aguiar-Morales J
    Breast J; 2004; 10(4):375-6. PubMed ID: 15239804
    [No Abstract]   [Full Text] [Related]  

  • 8. Circulating tumor markers in breast cancer.
    Tondini C; Hayes DF; Kufe DW
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):653-74. PubMed ID: 2691493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results.
    Zervoudis S; Peitsidis P; Iatrakis G; Panourgias E; Koureas A; Navrozoglou I; Dubois JB
    J BUON; 2007; 12(4):487-92. PubMed ID: 18067207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The "false positive" tumor marker in malignant testicular tumor].
    Bussar-Maatz R; Weissbach L; Dahlmann N; Mann K
    Urologe A; 1993 May; 32(3):177-82. PubMed ID: 8511831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of the tumor marker TAG-72 in head and neck neoplasms].
    Altissimi G; von Garrel C
    HNO; 1990 Oct; 38(10):364-6. PubMed ID: 2283330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Important matters to identify robust markers for metastasis and recurrence in solid cancer.
    Mimori K; Iwatsuki M; Yokobori T; Mori M
    Ann Surg Oncol; 2009 Apr; 16(4):1070-1. PubMed ID: 19169757
    [No Abstract]   [Full Text] [Related]  

  • 13. [After-care of colorectal carcinoma--value of tumor markers].
    Köhne CH; Benter T
    Internist (Berl); 1997 Apr; 38(4):363-5. PubMed ID: 9213578
    [No Abstract]   [Full Text] [Related]  

  • 14. Circulating cancer cells: could they be used in the clinic as recurrence markers for gastric and colorectal cancer?
    Hanisch E; Hottenrott C; Roukos DH
    Ann Surg Oncol; 2009 Mar; 16(3):778-9; author reply 780-2. PubMed ID: 19116754
    [No Abstract]   [Full Text] [Related]  

  • 15. [What are tumor markers, and what is their value?].
    von Kleist S
    Wien Klin Wochenschr; 1989 Jul; 101(14):459-63. PubMed ID: 2672605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biomarkers in the control of the treatment of gastrointestinal carcinomas].
    Lorenzi M; Inaudi P; Caldarone R; Garzi A; Lorenzini L
    Minerva Chir; 1987 Oct; 42(20):1621-4. PubMed ID: 3683923
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatoma-related gamma-glutamyl transferase in laboratory or clinical diagnosis of hepatocellular carcinoma.
    Yao DF; Dong ZZ
    Hepatobiliary Pancreat Dis Int; 2007 Feb; 6(1):9-11. PubMed ID: 17287158
    [No Abstract]   [Full Text] [Related]  

  • 18. [The pre- and postoperative and follow-up use of the tumor markers MCA, CA-125 and CA-19-9].
    Zanon C; Alluminio P; Margarita V; Sottimano C; Giuliani F; Neri G; Ballario F
    Minerva Chir; 1992 Jan; 47(1-2):27-30. PubMed ID: 1553049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment monitoring of patients with uterine cancer with and without progression by free serum amino acids].
    Elling D; Bader K
    Zentralbl Gynakol; 1989; 111(18):1224-30. PubMed ID: 2588854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEA, TPA, CA 19-9, SCC and CYFRA at diagnosis and in the follow-up of anal canal tumors.
    Indinnimeo M; Reale MG; Cicchini C; Stazi A; Fiori E; Izzo P
    Int Surg; 1997; 82(3):275-9. PubMed ID: 9372374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.